PDF herunterladen
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2005; 26(02): 28-30
DOI: 10.1055/s-0041-1733118
Selected Summary

Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma

Roopa Hariprasad
Department of Medical Oncology, IRCH, All India Institute of Medical sciences, New Delhi, India
,
Lalit Kumar
Department of Medical Oncology, IRCH, All India Institute of Medical sciences, New Delhi, India
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
  als PDF herunterladen Lizenzen und Reprints


Publikationsverlauf

Artikel online veröffentlicht:
28. März 2022

© 2005. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Cannistra SA, cancer of the ovary NEJM2004,351:25192529
  • 2 Griffiths CT, parker LM, Lee S, Finkler NJ. Effect of residual mass size on response to chemotherapy after surgical cytoreduction for advanced ovarian cancer: long term results. Int J Gynecol cancer 2002;12:323-31.
  • 3 Allen DG, Heinz APM, Touw FWMM. A metaanalysis of residual disease and survival in stage III & IV carcinoma of the ovary Eur J Gynecol Oncol 1995;16:349-56.
  • 4 Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-1259.
  • 5 Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncology 2000;78:269-74.
  • 6 van der Burg MEL, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer N Engl J Med 1995;332:629-634.
  • 7 Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, et al. for the Gynecologic Oncology Group. Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma. N Eng J Med 2004;351:2489-97
  • 8 McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
  • 9 Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin- cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708.
  • 10 Janga D, Kumar L, Kumar S, Shukla NK, Thulkar S, Singh R. Neo-adjuvant chemotherapy in advanced epithelial ovarian cancer (EOC) prospective randomized study: Proc Am Soc Clin Oncol 2004; Vol. 23:5123,478 (abst).